Recent Advances in SARS-CoV-2-Induced Immune Thrombocytopenia --Review.
10.19746/j.cnki.issn.1009-2137.2023.02.042
- Author:
Xin-Hui ZHOU
1
;
Chang-Geng RUAN
1
;
Yang HE
2
Author Information
1. Department of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215006, Jiangsu Province, China.
2. Department of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215006, Jiangsu Province, China .E-mail: heyang1963@163.com.
- Publication Type:Journal Article
- Keywords:
immune thrombocytopenia;
SARS-CoV-2;
autoimmune disease
- MeSH:
Humans;
Purpura, Thrombocytopenic, Idiopathic/drug therapy*;
SARS-CoV-2;
COVID-19/complications*;
Thrombocytopenia;
Thrombosis/drug therapy*;
Thrombopoietin/therapeutic use*;
Recombinant Fusion Proteins/therapeutic use*
- From:
Journal of Experimental Hematology
2023;31(2):593-597
- CountryChina
- Language:Chinese
-
Abstract:
SARS-CoV-2-induced immune thrombocytopenia (SARS-CoV-2-induced ITP) is an autoimmune disease secondary to virus infections. Its diagnosis is often based on exclusion of other possible causes of thrombocytopenia in COVID-19 patients. Common laboratory examinations include coagulation function, thrombopoietin and drug-dependent antibodies. Since both bleeding and thrombosis risks are seen in SARS-CoV-2-induced ITP patients, individual remedy is essential for the treatment of this disease. Because thrombopoietin receptor agonist(TPO-RA) has the side effect of accelerating thrombosis and may aggravate the pulmonary embolism symptoms of patients, it should be used for refractory SARS-CoV-2-induced ITP patients only. This review briefly summarizes the recent research progress in the pathogenesis, diagnosis and treatment of SARS-CoV-2-induced ITP.
